{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"24.860","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"1,117,628,030","primaryexch":"香港交易所","ric":"9688.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BP8L269","am":"217.50","iv":"","ew_strike":"","as":"24.340","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"24.320","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"100","update_time":"2025-09-28 00:06:03.0","lo52":"15.500","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"杜瑩","underlying_ric":"9688.HK","hi52":"35.500","issuer_name":"再鼎醫藥有限公司","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"24.160","mkt_cap":"27.18","f_aum_hkd":null,"ew_sub_per_to":"","ls":"24.320","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.880","aum":"","issued_shares_class_B":null,"vo":"8.90","secondary_listing_flag":false,"listing_date":"2020年9月28日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"再鼎醫藥有限公司","nm_s":"再鼎醫藥","sym":"9688","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.020","strike_price":"","summary":"再鼎醫藥有限公司是一家主要從事生物製藥的控股公司。該公司致力於通過產品的發現、開發和商業化解決腫瘤、自身免疫疾病、感染性疾病和中樞神經系統疾病領域未被滿足的醫療需求。該公司擁有從發現階段到臨床項目後期的一系列專利候選藥物。其中包括“則樂”、“OPTUNE”、“擎樂”、“紐再樂”及“衛偉迦”等","op":"24.620","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港北角<br/>英皇道510號<br/>港運大廈<br/>23樓2301室","pc":"-3.49","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"USD","hdr":false,"launch_date":"","hc":"25.200","isin":"KYG9887T1168","moneyness":""}},"qid":"1759074076682"}
